NO302701B1 - Kinuklidin-derivater - Google Patents

Kinuklidin-derivater

Info

Publication number
NO302701B1
NO302701B1 NO934312A NO934312A NO302701B1 NO 302701 B1 NO302701 B1 NO 302701B1 NO 934312 A NO934312 A NO 934312A NO 934312 A NO934312 A NO 934312A NO 302701 B1 NO302701 B1 NO 302701B1
Authority
NO
Norway
Prior art keywords
quinuclidine derivatives
quinuclidine
derivatives
Prior art date
Application number
NO934312A
Other languages
English (en)
Norwegian (no)
Other versions
NO934312L (no
NO934312D0 (no
Inventor
Fumitaka Ito
Hiroshi Kondo
Kaoru Shimada
Masami Nakane
Iii John Adams Lowe
Terry J Rosen
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24845673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO302701(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of NO934312L publication Critical patent/NO934312L/no
Publication of NO934312D0 publication Critical patent/NO934312D0/no
Publication of NO302701B1 publication Critical patent/NO302701B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO934312A 1991-05-31 1993-11-29 Kinuklidin-derivater NO302701B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70840491A 1991-05-31 1991-05-31
PCT/US1992/003317 WO1992021677A1 (fr) 1991-05-31 1992-04-28 Derives de quinuclidine

Publications (3)

Publication Number Publication Date
NO934312L NO934312L (no) 1993-11-29
NO934312D0 NO934312D0 (no) 1993-11-29
NO302701B1 true NO302701B1 (no) 1998-04-14

Family

ID=24845673

Family Applications (2)

Application Number Title Priority Date Filing Date
NO934312A NO302701B1 (no) 1991-05-31 1993-11-29 Kinuklidin-derivater
NO2007003C NO2007003I2 (no) 1991-05-31 2007-03-09 Maropitant eller et farmasøytisk akseptabelt salt av denne forbindelsen, inkludert citrat monohydratsalt

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2007003C NO2007003I2 (no) 1991-05-31 2007-03-09 Maropitant eller et farmasøytisk akseptabelt salt av denne forbindelsen, inkludert citrat monohydratsalt

Country Status (41)

Country Link
US (3) US5807867A (fr)
EP (1) EP0587723B1 (fr)
JP (2) JPH0733386B2 (fr)
KR (1) KR100214905B1 (fr)
CN (1) CN1048492C (fr)
AP (1) AP299A (fr)
AT (1) ATE135006T1 (fr)
AU (1) AU657552B2 (fr)
BG (1) BG61694B1 (fr)
BR (1) BR9206073A (fr)
CA (1) CA2102179C (fr)
CZ (1) CZ281403B6 (fr)
DE (4) DE69208877T2 (fr)
DK (1) DK0587723T3 (fr)
EG (1) EG19944A (fr)
ES (1) ES2084361T3 (fr)
FI (1) FI114475B (fr)
GR (1) GR3019687T3 (fr)
GT (1) GT199200028A (fr)
HU (1) HU217548B (fr)
IE (1) IE72473B1 (fr)
IL (1) IL102008A (fr)
IS (1) IS1611B (fr)
LU (1) LU91293I2 (fr)
MA (1) MA22539A1 (fr)
MX (1) MX9202554A (fr)
NL (1) NL300250I2 (fr)
NO (2) NO302701B1 (fr)
NZ (2) NZ242956A (fr)
OA (1) OA09867A (fr)
PL (1) PL171379B1 (fr)
PT (1) PT100546B (fr)
RO (1) RO110499B1 (fr)
RU (1) RU2103269C1 (fr)
SK (1) SK390692A3 (fr)
TW (1) TW204349B (fr)
UA (1) UA27776C2 (fr)
UY (1) UY23422A1 (fr)
WO (1) WO1992021677A1 (fr)
YU (1) YU48995B (fr)
ZA (1) ZA923942B (fr)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102179C (fr) * 1991-05-31 1998-10-27 Fumitaka Ito Derives quinuclidine
HU224443B1 (hu) * 1991-06-20 2005-09-28 Pfizer Inc. Fluor-alkoxi-benzaldehid-származékok
US5721255A (en) * 1992-08-19 1998-02-24 Pfizer Inc. Substituted benzylamino nitrogen containing non-aromatic heterocycles
US5886009A (en) * 1992-11-12 1999-03-23 Pfizer Inc. Quinuclidine derivative as a substance P antagonist
US5344830A (en) * 1992-12-10 1994-09-06 Merck & Co., Inc. N,N-diacylpiperazine tachykinin antagonists
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0653208A3 (fr) * 1993-11-17 1995-10-11 Pfizer Antagonistes de la substance P pour le traitement et la prévention de l'erythème solaire.
EP0659409A3 (fr) * 1993-11-23 1995-08-09 Pfizer Antagonistes de la substance P pour l'inhibition de l'angiogénése.
EP0655246A1 (fr) * 1993-11-30 1995-05-31 Pfizer Inc. Antagonistes de la substance P pour le traitement des maladies causées par Helicobacter Pylori ou d'autres bacteries spirales, ureare-positives, gram-négatives
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
IL123740A0 (en) * 1997-03-28 1998-10-30 Pfizer NK-1 receptor antagonists for the treatment of delayed emesis
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
KR20010041991A (ko) * 1998-03-19 2001-05-25 다케다 야쿠힌 고교 가부시키가이샤 복소환식 화합물, 그의 제조법 및 타키키닌 수용체길항약으로서의 용도
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
CA2324116A1 (fr) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Antagonistes du recepteur nk-1 et eletriptan pour le traitement de la migraine
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
WO2001032625A1 (fr) 1999-11-03 2001-05-10 Du Pont Pharmaceuticals Company Tetrahydroisoquinolines a substitution aryle et heteroaryle et utilisation de ces composes pour bloquer le recaptage de norepinephrine, de dopamine et de serotonine
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
JP5132864B2 (ja) 2000-07-11 2013-01-30 アルバニー モレキュラー リサーチ， インコーポレイテッド ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (fr) * 2000-09-28 2003-03-26 Pfizer Products Inc. Composition pour le traitement de la dépression et de l'anxieté contenant un antagoniste du recepteur NK-3 et un antagoniste du récepteur NK-1
KR20040029375A (ko) * 2001-07-20 2004-04-06 화이자 프로덕츠 인코포레이티드 개, 고양이 및 말에서 결함있는 행태를 변화시키기 위한ｎｋ-1 수용체 길항제의 용도
US6686507B2 (en) 2002-03-06 2004-02-03 Pfizer Inc Purification of 2-methoxy-5-trifluoromethoxybenzaldehyde
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
NZ569331A (en) * 2003-01-21 2010-08-27 Yeda Res & Dev COP 1 for treatment of inflammatory bowel diseases
US20050136487A1 (en) * 2003-10-27 2005-06-23 Meyer Donald W. Transmissible spongiform encephalopathy detection in cervids, sheep and goats
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
KR100880391B1 (ko) * 2004-01-30 2009-01-30 화이자 프로덕츠 인크. 마취 회복 개선용 ｎｋ-1 수용체 길항제
ES2638113T3 (es) * 2004-01-30 2017-10-18 Zoetis Services Llc Conservantes antimicrobianos para lograr una formulación de dosis múltiples usando ciclodextrinas beta para formas de dosificación líquidas
ES2296131T3 (es) * 2004-02-02 2008-04-16 Pfizer Products Incorporated Procedimiento para la preparacion de 1-(2s,3s)-2-bencidril-n-(5-terc-butil-2-metoxibencil)quinuclidin-3-amina.
AU2005274927B2 (en) 2004-07-15 2011-11-03 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh) 2006-11-30 2008-06-04 深圳市鼎兴生物医药技术开发有限公司 胆碱酯酶在拮抗速激肽药物中的应用
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
JP2010516731A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (fr) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibiteurs de l'activité akt
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
WO2010132487A1 (fr) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company Formes cristallines de (s)-7-([1,2,4]triazolo[1,5-a] pyridin -6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et leurs utilisations
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
EP2584903B1 (fr) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (fr) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (fr) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (fr) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
EP2654748B1 (fr) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
EP2699567A1 (fr) 2011-04-21 2014-02-26 Merck Sharp & Dohme Corp. Inhibiteurs du récepteur du facteur de croissance 1 analogue à l'insuline
ES2672099T3 (es) 2011-07-04 2018-06-12 Irbm - Science Park S.P.A. Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal
WO2013063214A1 (fr) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
EP3358013B1 (fr) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
WO2014078568A1 (fr) 2012-11-14 2014-05-22 The Johns Hopkins University Méthodes et compositions pour le traitement de la schizophrénie
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
EP2935263B1 (fr) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Imidazopyridines substituées en tant qu'inhibiteurs d'hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
WO2018071283A1 (fr) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
IL312486B2 (en) 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
CN106977512B (zh) * 2017-05-04 2019-01-01 海门慧聚药业有限公司 制备马罗匹坦游离碱的方法
IL271464B2 (en) 2017-06-30 2024-08-01 Chase Therapeutics Corp NK-1 antagonist compositions and methods for use in the treatment of depression
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3758688B1 (fr) 2018-02-26 2024-03-27 Ospedale San Raffaele S.r.l. Antagonistes nk-1 destinés à être utilisés dans le traitement de la douleur oculaire
KR102102109B1 (ko) * 2018-07-10 2020-04-20 성균관대학교산학협력단 N-벤즈히드릴 퀴뉴클리딘 유도체를 포함하는 나트륨 누출 채널 억제용 조성물
EP3833668B1 (fr) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
EP4117673A1 (fr) 2020-03-11 2023-01-18 Ospedale San Raffaele S.r.l. Traitement d'une déficience en cellules souches
AT527172A1 (de) 2023-04-25 2024-11-15 Vetviva Richter Gmbh Maropitantformulierung

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (fr) * 1988-11-23 1990-05-31 Pfizer Inc. Derives de quinuclidine en tant qu'antagonsites de substance p
AU648317B2 (en) * 1990-06-01 1994-04-21 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
DE4026743A1 (de) * 1990-08-24 1992-02-27 Teves Gmbh Alfred Blockiergeschuetzte bremsanlage fuer kraftfahrzeuge
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
CA2102179C (fr) * 1991-05-31 1998-10-27 Fumitaka Ito Derives quinuclidine
EP1082959A1 (fr) * 1991-09-20 2001-03-14 Glaxo Group Limited Utilisation des NK1-antagonistes pour le traitement de la depression
GB9218334D0 (en) * 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (fr) * 1993-11-30 1995-05-31 Pfizer Inc. Antagonistes de la substance P pour le traitement des maladies causées par Helicobacter Pylori ou d'autres bacteries spirales, ureare-positives, gram-négatives
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
US5990125A (en) * 1996-01-19 1999-11-23 Pfizer Inc. NK-1 receptor antagonists for the treatment of cancer
PT785198E (pt) * 1996-01-19 2000-11-30 Lonza Ag Processo para a producao de 3-quinuclidinol opticamente activo.

Also Published As

Publication number Publication date
IS1611B (is) 1996-10-18
BG61694B1 (bg) 1998-03-31
GT199200028A (es) 1993-11-20
MA22539A1 (fr) 1992-12-31
DE9290063U1 (de) 1994-02-24
AP299A (en) 1994-01-14
NO934312L (no) 1993-11-29
KR100214905B1 (ko) 1999-08-02
US5807867A (en) 1998-09-15
DE69208877D1 (de) 1996-04-11
SK278788B6 (sk) 1998-02-04
PT100546A (pt) 1993-08-31
AP9200384A0 (en) 1992-07-31
NZ270673A (en) 1997-07-27
US6222038B1 (en) 2001-04-24
NZ242956A (en) 1995-06-27
SK390692A3 (en) 1998-02-04
DE122006000066I1 (de) 2007-03-22
CZ390692A3 (en) 1994-02-16
EP0587723B1 (fr) 1996-03-06
EG19944A (en) 1997-02-27
NL300250I1 (nl) 2007-02-01
IE72473B1 (en) 1997-04-23
UY23422A1 (es) 1992-11-12
JPH0733386B2 (ja) 1995-04-12
FI114475B (fi) 2004-10-29
ZA923942B (en) 1993-11-29
CZ281403B6 (cs) 1996-09-11
AU1990192A (en) 1993-01-08
JPH07285965A (ja) 1995-10-31
IE921729A1 (en) 1992-12-02
CN1048492C (zh) 2000-01-19
TW204349B (fr) 1993-04-21
NO2007003I1 (no) 2007-03-26
US5939433A (en) 1999-08-17
LU91293I2 (fr) 2007-02-06
OA09867A (en) 1994-08-15
PL171379B1 (en) 1997-04-30
NO2007003I2 (no) 2011-04-18
CA2102179A1 (fr) 1992-12-01
AU657552B2 (en) 1995-03-16
HUT70151A (en) 1995-09-28
ATE135006T1 (de) 1996-03-15
IL102008A (en) 1995-12-08
RU2103269C1 (ru) 1998-01-27
BG98248A (bg) 1994-07-29
RO110499B1 (ro) 1996-01-30
CA2102179C (fr) 1998-10-27
DE69208877T2 (de) 1996-07-25
NO934312D0 (no) 1993-11-29
IS3871A (is) 1992-12-02
UA27776C2 (uk) 2000-10-16
FI935297L (fi) 1993-11-29
MX9202554A (es) 1992-11-01
GR3019687T3 (en) 1996-07-31
DE122006000066I2 (de) 2007-12-06
FI935297A0 (fi) 1993-11-29
EP0587723A1 (fr) 1994-03-23
JPH06504292A (ja) 1994-05-19
DK0587723T3 (da) 1996-04-01
HU217548B (hu) 2000-02-28
PT100546B (pt) 1999-12-31
NL300250I2 (nl) 2007-03-01
BR9206073A (pt) 1994-12-06
ES2084361T3 (es) 1996-05-01
IL102008A0 (en) 1992-12-30
YU56492A (sh) 1995-03-27
YU48995B (sh) 2003-04-30
HU9303393D0 (en) 1994-03-28
CN1067428A (zh) 1992-12-30
JP2645225B2 (ja) 1997-08-25
WO1992021677A1 (fr) 1992-12-10

Similar Documents

Publication Publication Date Title
DK0587723T3 (da) Quinuclidinderivater
FI924160A7 (fi) Benzanilidderivat
FI935726A7 (fi) Atsanorbornaanijohdannaisia
FI924159L (fi) Benzanilidderivat
NO922182L (no) Krystallinske oksatiolan-derivater
FI933067A7 (fi) Absorptionsprodukt med snabbt fungerande absorberande innedel i flera skikt
FI925422L (fi) Indolopyrrolokarbazolderivat
FI921262L (fi) 4-aryltiazol- eller 4-arylimidazolderivat
NO924890D0 (no) Imidazopyridiner
FI925763L (fi) Fungicida 2-imidazolin-5-on- och 2-imidazolin-5-tionderivat
FI923726L (fi) Sulfaterade glykosaminoglykanoidderivat
FI930345L (fi) Foerfarande foer framstaellning av renat akrylamidosulfonsyramonomerderivat
ATA131391A (de) Reibring
FI923342L (fi) Pleuromutilinkomplex
FI935243L (fi) Pyridonkarboxylsyraderivat
TR26336A (tr) SüBSTITüE EDILMIS PIRAZOLIN TüREVLERI
FI925314A7 (fi) Cefalosporinderivat
DE69222599D1 (de) Cephalosporin-Derivate
FI920394A7 (fi) 3-kinuklidiinijohdannaiset
DE59207540D1 (de) Resolver
MX9206710A (es) Derivados de piridinol
FI924145L (fi) 3-cykloalkylprop-2-enamidderivat
FI921597A7 (fi) Maetning av en hisskorgs position med hjaelp av ultraljud
FI935293A7 (fi) Propensyraderivat
FI942070L (fi) Nitroksialkyyliamidijohdannaiset

Legal Events

Date Code Title Description
SPCF Filing of supplementary protection certificate

Free format text: PRODUCT NAME: CERENIA-MAROPITANT; NAT. REG. NO/DATE: EU206062001/NO-005/NO 20061031; FIRST REG. NO/DATE: BE , EU206062001-005 20060929

Spc suppl protection certif: 2007003

Filing date: 20070309

SPCG Granted supplementary protection certificate

Free format text: PRODUCT NAME: CERENIA-MAROPITANT; NAT. REG. NO/DATE: EU206062001/NO-005/NO 20061031; FIRST REG. NO/DATE: BE , EU206062001-005 20060929

Spc suppl protection certif: 2007003

Filing date: 20070309

Extension date: 20170428

MK1K Patent expired
SPCX Expiry of an spc

Spc suppl protection certif: 2007003